KLRK1 and type 1 diabetes mellitus: Such an understanding will help avoid side effects and improve the efficacy of therapies such as NKG2D chimeric antigen receptor T cells, which are being developed to target tumors, and anti-NKG2D mAbs, which are being evaluated for the treatment of Crohn’s disease and type I diabetes (77–81).